Research programme: cephalosporin antibacterials - Yungjin Pharm
Alternative Names: YJP-40102Latest Information Update: 16 Jul 2016
At a glance
- Originator Yung-Jin Pharmaceutical
- Class
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Gram-positive-infections in South Korea
- 16 Jul 2016 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in South Korea
- 24 Jan 2006 Preclinical trials in Gram-positive infections in South Korea (unspecified route)